Tocilizumab for the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 4, Issue 2, 2008, Pages 165-172

  Mima, Toru ^a   Nishimoto, Norihiro ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Anticytokine therapy; Biologics; IL 6; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ABATACEPT; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B E8; PLACEBO; TUMOR NECROSIS FACTOR DERIVATIVE;

ABNORMAL LABORATORY RESULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; GASTROENTERITIS; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFECTION; INJECTION SITE REACTION; JOINT DESTRUCTION; JOINT RADIOGRAPHY; LYMPHADENOPATHY; MONOTHERAPY; NONHUMAN; PHARMACODYNAMICS; PNEUMONIA; REPEATED DRUG DOSE; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; VIRUS REACTIVATION;

EID: 46149091297     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.2.165     Document Type: Article

References (64)

1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 4, 130-136 (2005).
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
3. McInnes IB, Liew F. Cytokine networks - towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1, 31-39 (2005).
4. Aud D, Peng SL. Mechanisms of disease: transcription factors in inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 2, 434-442 (2006).
5. Houssiau FA, Devogelear JP, van Damne J, de Deuxchaisnes CN, van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31, 784-788 (1988).
6. Brozik M, Rosztoczy I, Meretey K et al. Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production. J. Rheumatol. 19, 63-68 (1992).
7. Sack U, Kinne RW, Marx, T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int. 13, 45-51 (1993).
8. Steiner G, Tohidast-Akrad M, Witzmann G et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38, 202-213 (1999).
9. Gueme PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 83, 585-592 (1989).
10. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 52, 232-234 (1993).
11. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J. Rheumatol. 19, 22-25 (1992).
12. Hirano T, Yasukawa K, Harada H et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immmunoglobulin. Nature 324, 73-76 (1986).
13. Muraguchi A, Hirano T, Tang B et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 167, 332-344 (1988).
14. Wolvekamp MC, Marquet RL. Interleukin-6: historical background, genetics and biological significance. Immunol. Lett. 24, 1-10 (1990).
15. Kishimoto T. The biology of interleukin-6. Blood 74, 1-10 (1989).
16. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv. Immunol. 54, 1-78 (1993).
17. Le J, Fredrickson G, Luiz FL et al. Interleukin 2-dependent and interleukin 2-independent pathways of regulation of thymocyte function by interleukin 6. Proc. Natl Acad. Sci. USA 85, 8643-8647 (1988).
18. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/ BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 141, 1543-1549 (1998).
19. Andus T, Geiger T, Hirano T et al. Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-β2) regulates β-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett. 221, 18-22 (1987).
20. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 265, 621-636 (1990).
21. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271-1276 (2004).
22. Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl Acad. Sci. USA. 90, 11924-11928 (1993).
23. Koch AE, Harlow LA, Haines GK et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149-4156 (1994).
24. Ballara S, Taylor PC, Reusch P et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 44, 2055-2064 (2001).
25. Nakahara H, Song J, Sugimoto M et al. Anti-interleukin-6 receptor antibody therapy reduced vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48, 1521-1529 (2003).
26. Sugita T, Furukawa O, Ueno M, Murakami T, Takata I, Tosa T. Enhanced expression of interleukin 6 in rat and murine arthritis model. Int. Immunopharmacol. 15, 469-476 (1993).
27. Alonizi T, Fattori E, Lazzaro D et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468 (1998).
28. Sasai M, Saeki Y, Ohshima S et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6 deficient mice. Arthritis Rheum. 42, 1635-1643 (1999).
29. Takagi N, Mihara M, Moriya Y et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41, 2117-2121 (1998).
30. Hata H, Sakaguchi N, Yoshitomi H et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J. Clin. Invest. 114, 582-588 (2004).
31. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218-1222 (2006).
32. + Th cells that cause autoimmune arthritis. J. Exp. Med. 204, 41-47 (2007).
33. Atumi T, Ishihara K, Kamimura D et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196, 979-990 (2002).
34. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis. fact or fiction? Arthritis Rheum. 52, 2975-2983 (2005).
35. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005).
36. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis. Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54, 1786-1794 (2006).
37. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison o etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis Rheum. 54, 1063-1074 (2006).
38. Weyand CM, Groronzy JJ. T-cell-targeted therapies in rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2, 201-210 (2006).
39. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2, 20-27 (2006).
40. Bayry J, Lacroix-Desmazes S, Kazatckine MD, Kaveri S. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic disease: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3, 262-272 (2007).
41. Nishimoto N, Kishimoto T. Interleukin-6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2, 619-626 (2006).
42. Wendling D, Racadot E, Winjdenes J. Treatment of severe rheumatoid arthritis by and-interleukin 6 monoclonal antibody. J. Rheumatol. 20, 259-262 (1993).
43. Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today 42, 559-576 (2006).
44. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin. Immunopathol. 20, 247-259 (1998).
45. Mihara M, Kotoh M, Nishimoto N et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin. Immunol. 98, 319-326 (2001).
46. Matuno H, Sawai T. Nezuka T et al. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody. Arthritis Rheum. 41, 2014-2021 (1998).
47. Murakami M, Hibi N, Nakagawa N et al. IL- 6-induced homodimerization of gp130 and associated activation of tyrosine kinase. Science 260, 1808-1810 (1993).
48. Taga T, Hibi M, Hirata Y et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell 58, 573-581 (1989).
49. Taga T, Kishimoto T. gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15, 797-819 (1997).
50. Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune disease by anti-interleukin-6 receptor antibody. Expert. Opin. Biol Ther. 5, 683-690 (2005).
51. Nishimoto N, Yoshizaki Y, Maeda K et al. Toxicity, phamacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody mra in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 30, 1426-1435 (2003).
52. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr. Opin. Rehumatol. 18, 277-281 (2006).
53. Choy EH, Isenberg DA, Garrood DA et al. Therapeutic benefit of blocking interleukin-6 activity with an and-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46, 3143-3150 (2002).
54. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
55. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizurnab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817-2829 (2006).
56. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomized controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162-1167 (2007).
57. Ogawa J, Harigai M, Akashi T et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanized anti- interleukin-6 receptor monoclonal antibody. Ann. Rheum. Dis. 65, 1667-1669 (2006).
58. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358, 24-29 (2001).
59. Moshage HJ, Roelofs HM, van Pelt JF et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem. Biophy Res. Commun. 155, 112-117 (1988).
60. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 54, 2997-3000 (2006).
61. Dankbar B, Padro T, Leo R et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95, 2630-2636 (2000).
62. Adachi Y, Aoki C, Yoshio-Hoshino N et al. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int. J. Cancer 119, 1303-1311 (2006).
63. Wei LH, Kuo ML, Chen CA et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 22, 1517-1527 (2003).
64. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int. J. Cancer 111, 653-661 (2004).